Prospective Study
Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 28, 2020; 26(44): 7061-7075
Published online Nov 28, 2020. doi: 10.3748/wjg.v26.i44.7061
Table 1 Baseline characteristic
Group Q1 Q2 Q3 Q4 SUA level (mg/dL) (1.50, 4.20) (4.20, 5.09) (5.09, 6.06) (6.06, 17.90) Number 111087 110975 111241 111159 Gender Male 99225 (89.3%) 73883 (66.6%) 44282 (39.8%) 21466 (19.3%) Female 11862 (10.7%) 37092 (33.4%) 66959 (60.2%) 89693 (80.7%) Mean age (SD) 55.30 (8.20) 56.90 (8.00) 57.50 (7.97) 57.70 (8.00) White European 104975 (94.5%) 104411 (94.1%) 104447 (93.9%) 104475 (94.0%) Current smokers 11629 (10.5%) 11 95 (10.6%) 12154 (10.9%) 11444 (10.3%) Alcohol intake Over four times a week 40852 (36.8%) 45126 (40.7%) 49976 (44.9%) 57439 (51.7%) Once or twice a week 29330 (26.4%) 29071 (26.2%) 28787 (25.9%) 27396 (24.6%) One to three times a month 14577 (13.1%) 13324 (12.0%) 1 850 (10.7%) 9681 (8.7%) Seldom or never 26102 (23.5%) 23203 (20.9%) 20363 (18.3%) 16388 (14.7%) Fruit and vegetable intake Yes 47673 (42.9%) 44146 (39.8%) 40049 (36.0%) 35593 (32.0%) No 63175 (56.9%) 66545 (60.0%) 70869 (63.7%) 75234 (67.7%) Physical activity High 36219 (32.6%) 36706 (33.1%) 36948 (33.2%) 36029 (32.4%) Moderate 37562 (33.8%) 36235 (32.7%) 36318 (32.6%) 36115 (32.5%) Low 14838 (13.4%) 16003 (14.4%) 17162 (15.4%) 19457 (17.5%) Annual household income Less than £18000 20748 (18.7%) 21456 (19.3%) 21341 (19.2%) 21536 (19.4%) £18000 to £30999 23304 (21.0%) 24243 (21.8%) 24310 (21.9%) 24159 (21.7%) £31000 to £51999 24672 (22.2%) 24624 (22.2%) 25270 (22.7%) 25168 (22.6%) £52000 to £100000 19676 (17.7%) 18781 (16.9%) 19544 (17.6%) 20555 (18.5%) Greater than £100000 5132 (4.6%) 4947 (4.5%) 5211 (4.7%) 5666 (5.1%) College or University degree 38460 (34.6%) 36499 (32.9%) 35860 (32.2%) 33817 (30.4%) Family history of cancer 38048 (34.3%) 38942 (35.1%) 39465 (35.5%) 39063 (35.1%) Mean BMI, kg/m2 (SD) 25.10 (4.01) 26.80 (4.45) 28.10 (4.62) 29.60 (4.82)
Table 2 Baseline characteristic stratified by gender
Male Female Group Quartile 1 Quartile 2 Quartile 3 Quartile 4 Quartile 1 Quartile 2 Quartile 3 Quartile 4 SUA level (mg/dL) (1.50, 5.13) (5.13, 5.87) (5.87, 6.69) (6.69, 17.90) (1.50, 3.77) (3.77, 4.42) (4.42, 5.18) (5.18, 12.90) Number 51349 51445 51364 51448 59639 59627 59872 59718 Mean age (SD) 56.90 (8.23) 56.90 (8.23) 57.00 (8.17) 57.30 (8.13) 54.60 (8.18) 56.00 (8.05) 57.20 (7.83) 58.90 (7.33) White European 48082 (93.6%) 48342 (94.0%) 48405 (94.2%) 48480 (94.2%) 56435 (94.6%) 56437 (94.7%) 56340 (94.1%) 55787 (93.4%) Current smokers 7983 (15.5%) 6579 (12.8%) 5816 (11.3%) 5377 (10.5%) 5759 (9.7%) 5412 (9.1%) 5138 (8.6%) 4958 (8.3%) Alcohol intake Over four times a week 23146 (45.1%) 25543 (49.6%) 27432 (53.4%) 29611 (57.5%) 20964 (35.1%) 22423 (37.6%) 22866 (38.2%) 21408 (35.8%) Once or twice a week 13636 (26.6%) 13770 (26.8%) 13308 (25.9%) 12478 (24.3%) 15822 (26.5%) 15714 (26.4%) 15444 (25.8%) 14412 (24.1%) One to three times a month 5297 (10.3%) 4919 (9.6%) 4300 (8.4%) 3749 (7.3%) 8141 (13.7%) 7837 (13.1%) 7669 (12.8%) 7520 (12.6%) Seldom or never 9124 (17.8%) 7098 (13.8%) 6203 (12.0%) 5500 (10.7%) 14598 (24.5%) 13546 (22.7%) 13761 (23.0%) 16226 (27.2%) Fruit and vegetable intake Yes 16819 (32.8%) 16373 (31.8%) 15863 (30.9%) 15126 (29.4%) 26202 (43.9%) 26292 (44.1%) 25919 (43.3%) 24867 (41.6%) No 34326 (66.8%) 34910 (67.9%) 35318 (68.8%) 36183 (70.3%) 33328 (55.9%) 33228 (55.7%) 33826 (56.5%) 34704 (58.1%) Physical activity High 19424 (37.8%) 19002 (36.9%) 18382 (35.8%) 17317 (33.7%) 19204 (32.2%) 18936 (31.8%) 18096 (30.2%) 15541 (26.0%) Low 7605 (14.8%) 7864 (15.3%) 8360 (16.3%) 9204 (17.9%) 7781 (13.0%) 8103 (13.6%) 8586 (14.3%) 9957 (16.7%) Moderate 16226 (31.6%) 16580 (32.2%) 16858 (32.8%) 16777 (32.6%) 20402 (34.2%) 20063 (33.6%) 19842 (33.1%) 19482 (32.6%) Annual household income Less than £18000 10135 (19.7%) 8851 (17.2%) 8622 (16.8%) 9477 (18.4%) 10830 (18.2%) 10982 (18.4%) 11999 (20.0%) 14185 (23.8%) £18000 to £30999 11380 (22.2%) 11083 (21.5%) 11039 (21.5%) 10931 (21.2%) 12249 (20.5%) 12676 (21.3%) 13038 (21.8%) 13620 (22.8%) £31000 to £51999 12024 (23.4%) 12537 (24.4%) 12538 (24.4%) 12138 (23.6%) 13368 (22.4%) 13137 (22.0%) 12663 (21.2%) 11329 (19.0%) £52000 to £100000 9559 (18.6%) 10489 (20.4%) 10708 (20.8%) 10307 (20.0%) 10844 (18.2%) 10200 (17.1%) 9238 (15.4%) 7211 (12.1%) Greater than £100000 2471 (4.8%) 2874 (5.6%) 3002 (5.8%) 2921 (5.7%) 2839 (4.8%) 2704 (4.5%) 2397 (4.0%) 1748 (2.9%) College or university degree 18240 (35.5%) 18096 (35.2%) 17459 (34.0%) 15895 (30.9%) 21019 (35.2%) 20036 (33.6%) 18344 (30.6%) 15547 (26.0%) Family history of cancer 17522 (34.1%) 17651 (34.3%) 17911 (34.9%) 17933 (34.9%) 20375 (34.2%) 20767 (34.8%) 21329 (35.6%) 22030 (36.9%) Mean BMI, kg/m2 (SD) 26.30 (3.90) 27.30 (3.87) 28.20 (3.99) 29.60 (4.41) 24.60 (3.82) 25.90 (4.29) 27.40 (4.82) 30.30 (5.79)
Table 3 Effect of serum uric acid on hepatobiliary-pancreatic cancer
Cancer Group Cases Incidence1 HR (95%CI) Model 1 Model 2 Model 3 Liver Q1 42 5.76 1.00 (reference) 1.00 (reference) 1.00 (reference) Q2 62 8.45 1.08 (0.72-1.60) 1.08 (0.73-1.61) 1.00 (0.67-1.50) Q3 62 8.58 0.90 (0.59-1.36) 0.90 (0.59-1.36) 0.79 (0.52-1.21) Q4 95 13.12 1.20 (0.80-1.81) 1.18 (0.79-1.78) 0.98 (0.64-1.49) Estimated HR (per 1 mg/dL) 1.08 (0.97-1.19) 1.06 (0.96-1.17) 1.01 (0.91-1.13) Gallbladder Q1 13 1.78 1.00 (reference) 1.00 (reference) 1.00 (reference) Q2 15 2.05 1.02 (0.48-2.19) 1.01 (0.47-2.18) 0.98 (0.45-2.12) Q3 10 1.38 0.85 (0.37-1.97) 0.84 (0.36-1.93) 0.79 (0.33-1.86) Q4 18 2.49 1.52 (0.68-3.39) 1.45 (0.65-3.24) 1.32 (0.56-3.11) Estimated HR (per 1 mg/dL) 1.09 (0.87-1.35) 1.07 (0.86-1.33) 1.04 (0.82-1.31) Biliary tract Q1 11 1.51 1.00 (reference) 1.00 (reference) 1.00 (reference) Q2 19 2.59 1.36 (0.64-2.89) 1.37 (0.65-2.93) 1.32 (0.61-2.89) Q3 27 3.74 1.64 (0.78-3.47) 1.69 (0.80-3.58) 1.48 (0.68-3.22) Q4 17 2.35 0.94 (0.41-2.15) 0.99 (0.43-2.27) 0.75 (0.31-1.82) Estimated HR (per 1 mg/dL) 0.92 (0.76-1.13) 0.94 (0.77-1.14) 0.85 (0.69-1.05) Pancreas Q1 76 10.43 1.00 (reference) 1.00 (reference) 1.00 (reference) Q2 115 15.68 1.31 (0.97-1.75) 1.31 (0.98-1.76) 1.29 (0.96-1.73) Q3 155 21.45 1.68 (1.26-2.24) 1.69 (1.27-2.26) 1.61 (1.19-2.16) Q4 183 25.28 1.91 (1.42-2.58) 1.92 (1.43-2.59) 1.77 (1.29-2.42) Estimated HR (per 1 mg/dL) 1.15 (1.07-1.23) 1.15 (1.07-1.23) 1.12 (1.04-1.21)
Table 4 Effect of uric acid on hepatobiliary-pancreatic cancer stratified by gender
Gender Cancer Group Cases Incidence1 HR (95%CI) Model 1 Model 2 Model 3 Male Liver Quartile 1 44 13.12 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 39 11.71 0.89 (0.58-1.37) 0.92 (0.60-1.42) 0.87 (0.57-1.34) Quartile 3 29 8.67 0.65 (0.41-1.05) 0.68 (0.42-1.08) 0.61 (0.38-0.98) Quartile 4 53 15.78 1.16 (0.78-1.73) 1.17 (0.78-1.75) 0.96 (0.63-1.46) Estimated HR (per 1 mg/dL) 1.07 (0.95-1.21) 1.07 (0.95-1.21) 1.01 (0.89-1.15) Gallbladder Quartile 1 2 0.60 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 5 1.50 2.48 (0.48-12.80) 2.54 (0.93-6.94) 2.45 (0.90-6.70) Quartile 3 6 1.79 2.91 (0.59-14.41) 2.93 (1.14-7.56) 2.71 (1.05-6.98) Quartile 4 8 2.38 3.67 (0.78-17.30) 3.56 (1.47-8.58) 3.09 (1.28-7.46) Estimated HR (per 1 mg/dL) 1.20 (0.86-1.67) 1.17 (0.85-1.60) 1.11 (0.81-1.53) Biliary tract Quartile 1 13 3.88 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 10 3.00 0.77 (0.34-1.76) 0.80 (0.35-1.84) 0.81 (0.35-1.88) Quartile 3 9 2.69 0.69 (0.30-1.62) 0.74 (0.32-1.75) 0.69 (0.29-1.67) Quartile 4 11 3.27 0.82 (0.37-1.83) 0.89 (0.39-2.00) 0.75 (0.32-1.75) Estimated HR (per 1 mg/dL) 0.82 (0.64-1.07) 0.85 (0.65-1.10) 0.80 (0.61-1.04) Pancreas Quartile 1 68 20.28 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 62 18.61 0.91 (0.65-1.29) 0.93 (0.66-1.32) 0.93 (0.66-1.32) Quartile 3 80 23.92 1.18 (0.85-1.62) 1.20 (0.87-1.66) 1.15 (0.83-1.60) Quartile 4 76 22.62 1.06 (0.77-1.48) 1.08 (0.77-1.50) 1.04 (0.74-1.47) Estimated HR (per 1 mg/dL) 1.02 (0.93-1.12) 1.02 (0.93-1.12) 1.01 (0.91-1.12) Female Liver Quartile 1 20 5.06 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 21 5.35 0.87 (0.47-1.64) 0.87 (0.47-1.64) 0.86 (0.46-1.62) Quartile 3 23 5.86 1.06 (0.59-1.91) 1.05 (0.58-1.90) 1.02 (0.56-1.87) Quartile 4 32 8.21 1.22 (0.69-2.15) 1.16 (0.65-2.05) 1.09 (0.59-2.02) Estimated HR (per 1 mg/dL) 1.10 (0.93-1.31) 1.08 (0.91-1.28) 1.06 (0.88-1.28) Gallbladder Quartile 1 6 1.52 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 10 2.55 1.47 (0.53-4.06) 1.49 (0.72-3.10) 1.47 (0.71-3.06) Quartile 3 10 2.55 1.31 (0.47-3.61) 1.30 (0.63-2.72) 1.27 (0.61-2.65) Quartile 4 9 2.31 1.02 (0.36-2.88) 0.99 (0.46-2.10) 0.94 (0.44-2.00) Estimated HR (per 1 mg/dL) 1.20 (0.86-1.67) 1.17 (0.85-1.60) 1.01 (0.75-1.35) Biliary tract Quartile 1 4 1.01 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 8 2.04 1.77 (0.53-5.88) 1.78 (0.80-3.97) 1.66 (0.74-3.71) Quartile 3 6 1.53 1.19 (0.33-4.22) 1.17 (0.48-2.85) 0.98 (0.40-2.39) Quartile 4 13 3.34 2.24 (0.72-6.94) 2.33 (1.14-4.76) 1.65 (0.81-3.36) Estimated HR (per 1 mg/dL) 0.82 (0.64-1.07) 0.85 (0.65-1.1) 1.09 (0.81-1.48) Pancreas Quartile 1 35 8.86 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 36 9.17 0.93 (0.58-1.48) 0.93 (0.58-1.47) 0.91 (0.57-1.44) Quartile 3 64 16.29 1.51 (1.00-2.28) 1.50 (0.99-2.27) 1.43 (0.94-2.18) Quartile 4 108 27.71 2.27 (1.54-3.34) 2.25 (1.53-3.31) 2.04 (1.35-3.08) Estimated HR (per 1 mg/dL) 1.02 (0.93-1.12) 1.02 (0.93-1.12) 1.33 (1.21-1.47)
Table 5 Sensitivity analysis
Cancer Group HR (95%CI) Model 1 Model 2 Model 3 Liver Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 1.00 (0.64-1.55) 1.01 (0.65-1.57) 0.92 (0.59-1.43) Quartile 3 0.78 (0.49-1.24) 0.79 (0.50-1.25) 0.68 (0.42-1.08) Quartile 4 1.04 (0.66-1.63) 1.04 (0.66-1.63) 0.82 (0.51-1.31) Gallbladder Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 1.68 (0.66-4.28) 1.71 (0.67-4.36) 1.63 (0.63-4.21) Quartile 3 1.41 (0.51-3.89) 1.42 (0.52-3.93) 1.31 (0.46-3.72) Quartile 4 2.71 (1.02-7.21) 2.72 (1.03-7.23) 2.40 (0.85-6.80) Biliary tract Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 1.09 (0.48-2.47) 1.10 (0.49-2.51) 1.12 (0.48-2.61) Quartile 3 1.10 (0.48-2.50) 1.14 (0.50-2.60) 1.08 (0.46-2.55) Quartile 4 0.75 (0.31-1.82) 0.79 (0.32-1.93) 0.68 (0.26-1.75) Pancreas Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 1.26 (0.90-1.76) 1.26 (0.90-1.77) 1.25 (0.89-1.76) Quartile 3 1.76 (1.27-2.44) 1.77 (1.28-2.46) 1.71 (1.22-2.40) Quartile 4 2.09 (1.49-2.92) 2.11 (1.51-2.95) 1.96 (1.38-2.80)
Table 6 Sensitivity analysis stratified by gender
Gender Cancer Group HR (95%CI) Model 1 Model 2 Model 3 Male Liver Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 0.88 (0.55-1.40) 0.92 (0.57-1.46) 0.86 (0.54-1.38) Quartile 3 0.60 (0.36-1.01) 0.62 (0.37-1.05) 0.56 (0.33-0.94) Quartile 4 0.99 (0.63-1.55) 0.99 (0.63-1.56) 0.81 (0.51-1.29) Gallbladder Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 3.04 (0.32-29.21) 3.20 (0.90-11.35) 3.01 (0.85-10.67) Quartile 3 4.92 (0.57-42.13) 5.22 (1.78-15.28) 4.58 (1.57-13.41) Quartile 4 5.52 (0.66-45.96) 5.85 (2.08-16.43) 4.64 (1.65-13.03) Biliary tract Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 0.83 (0.34-1.99) 0.87 (0.36-2.10) 0.88 (0.36-2.17) Quartile 3 0.82 (0.34-1.97) 0.88 (0.36-2.15) 0.83 (0.33-2.06) Quartile 4 0.70 (0.28-1.73) 0.77 (0.30-1.93) 0.64 (0.24-1.68) Pancreas Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 1.04 (0.70-1.55) 1.07 (0.72-1.59) 1.06 (0.71-1.59) Quartile 3 1.37 (0.95-1.99) 1.41 (0.97-2.04) 1.33 (0.91-1.95) Quartile 4 1.15 (0.78-1.69) 1.17 (0.79-1.73) 1.11 (0.74-1.66) Female Liver Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 0.91 (0.45-1.81) 0.92 (0.46-1.85) 0.89 (0.44-1.78) Quartile 3 0.98 (0.50-1.92) 1.00 (0.51-1.95) 0.92 (0.47-1.83) Quartile 4 1.05 (0.55-2.00) 1.02 (0.53-1.96) 0.88 (0.43-1.76) Gallbladder Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 2.06 (0.53-7.98) 2.13 (0.55-8.24) 2.11 (0.54-8.20) Quartile 3 2.38 (0.64-8.81) 2.47 (0.66-9.15) 2.42 (0.64-9.15) Quartile 4 2.08 (0.56-7.74) 2.10 (0.56-7.85) 2.02 (0.51-8.08) Biliary tract Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 1.56 (0.46-5.33) 1.56 (0.45-5.33) 1.48 (0.43-5.09) Quartile 3 0.80 (0.20-3.22) 0.80 (0.20-3.23) 0.72 (0.18-2.97) Quartile 4 1.23 (0.36-4.26) 1.29 (0.37-4.47) 1.04 (0.27-3.96) Pancreas Quartile 1 1.00 (reference) 1.00 (reference) 1.00 (reference) Quartile 2 0.78 (0.47-1.32) 0.78 (0.46-1.31) 0.77 (0.46-1.29) Quartile 3 1.21 (0.77-1.92) 1.20 (0.76-1.90) 1.16 (0.73-1.85) Quartile 4 2.07 (1.37-3.13) 2.05 (1.35-3.10) 1.93 (1.24-3.01)
Citation: Huang CF, Huang JJ, Mi NN, Lin YY, He QS, Lu YW, Yue P, Bai B, Zhang JD, Zhang C, Cai T, Fu WK, Gao L, Li X, Yuan JQ, Meng WB. Associations between serum uric acid and hepatobiliary-pancreatic cancer: A cohort study. World J Gastroenterol 2020; 26(44): 7061-7075
URL: https://www.wjgnet.com/1007-9327/full/v26/i44/7061.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i44.7061